ANI Pharmaceuticals, Inc. (ANIP) Q4 FY25 Earnings Call

Cortrophin growth remains strong, but 2026 execution depends on gout-force deployment amid royalty and gross-margin pressure.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-28
Length60 minutes
EPS$1.98
EPS consensus$1.62
Revenue$247.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All ANIP earnings ยท Back to ANIP overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.